Progression-Free Survival Prolonged With Sacituzumab Govitecan Plus Pembrolizumab in TNBC

THURSDAY, Jan. 22, 2026-- For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields...